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Background: Cigarette smoking is associated with increased frequency and duration of viral respiratory infections,
but the underlying mechanisms are incompletely defined. We investigated whether smoking reduces expression by
human lung macrophages (Mø) of receptors for viral nucleic acids and, if so, the effect on CXCL10 production.
Methods: We collected alveolar macrophages (AMø) by bronchoalveolar lavage of radiographically-normal lungs of
subjects undergoing bronchoscopies for solitary nodules (n = 16) and of volunteers who were current or former
smokers (n = 7) or never-smokers (n = 13). We measured expression of mRNA transcripts for viral nucleic acid
receptors by real-time PCR in those AMø and in the human Mø cell line THP-1 following phorbol myristate acetate/
vitamin D3 differentiation and exposure to cigarette smoke extract, and determined TLR3 protein expression using
flow cytometry and immunohistochemistry. We also used flow cytometry to examine TLR3 expression in total lung
Mø from subjects undergoing clinically-indicated lung resections (n = 25). Of these, seven had normal FEV1 and
FEV1/FVC ratio (three former smokers, four current smokers); the remaining 18 subjects (14 former smokers; four
current smokers) had COPD of GOLD stages I-IV. We measured AMø production of CXCL10 in response to
stimulation with the dsRNA analogue poly(I:C) using Luminex assay.
Results: Relative to AMø of never-smokers, AMø of smokers demonstrated reduced protein expression of TLR3 and
decreased mRNA for TLR3 but not TLR7, TLR8, TLR9, RIG-I, MDA-5 or PKR. Identical changes in TLR3 gene expression
were induced in differentiated THP-1 cells exposed to cigarette smoke-extract in vitro for 4 hours. Among total lung
Mø, the percentage of TLR3-positive cells correlated inversely with active smoking but not with COPD diagnosis,
FEV1% predicted, sex, age or pack-years. Compared to AMø of never-smokers, poly(I:C)-stimulated production of
CXCL10 was significantly reduced in AMø of smokers.
Conclusions: Active smoking, independent of COPD stage or smoking duration, reduces both the percent of
human lung Mø expressing TLR3, and dsRNA-induced CXCL10 production, without altering other endosomal or
cytoplasmic receptors for microbial nucleic acids. This effect provides one possible mechanism for increased
frequency and duration of viral lower respiratory tract infections in smokers.
Trial registration: ClinicalTrials.gov NCT00281190, NCT00281203 and NCT00281229.
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Viral respiratory infections are major risk factors for
exacerbations of chronic obstructive pulmonary dis-
ease (COPD) and asthma [1,2], contributing to enor-
mous societal costs due to healthcare utilization and
reduced productivity. The frequency and duration of
viral respiratory infections is increased by cigarette
smoking [3-6] through multiple mechanisms, includ-
ing reduced mucociliary clearance, impaired produc-
tion of epithelial defensins, and decreased neutrophil
chemotaxis {reviewed in [7,8]}. Smoking also nega-
tively impacts host defense by alveolar macrophages
(AMø), a key phagocyte and source of inflammatory
mediators. Acting via both nicotinic cholinergic recep-
tors [9] and uncharacterized mechanisms [10], smok-
ing decreases pro-inflammatory cytokine release by
human AMø [11-13]. Cigarette smoke extract (CSE)
also blunts the ability of AMø to be activated by IFN-γ
produced by T cells and natural killer (NK) cells [14].
Whether smoking has additional effects predisposing to
viral respiratory infections is unknown.
We hypothesized that cigarette smoke could also
reduce the ability of AMø to detect and activate innate
responses to respiratory viruses. Cells recognize viruses
by sensing double-stranded (ds) RNA using TLR3,
which is expressed on endosomes and in some cell
types, on the cell surface [15,16]. The other endosomal
microbe-associated molecular pattern (MAMP) recep-
tors, TLR7, TLR8 and TLR9, are also important for
recognizing single stranded RNA and bacterial DNA
with unmethylated CpG dinucleotides, respectively. Al-
ternatively, dsRNA can also be recognized via cytosolic
sensors, such as double-stranded RNA-dependent pro-
tein kinase R (PKR), retinoic acid-inducible gene I
(RIG-I), or melanoma differentiation-associated gene 5
(MDA-5) [17].
Experimentally, the response to dsRNA is measured
using the synthetic analogue polyinosinic acid:cytidylic
acid (poly(I:C)), which stimulates secretion of the che-
mokine CXCL10 (formerly IP-10) [18-20], in some
cell types in an entirely TLR3-dependent fashion [21].
CXCL10 is important to recruit and activate neutro-
phils, lymphocytes and NK cells [22-24], which are
crucial to limit viral replication. At concentrations
100-fold higher than needed for chemotactic activity,
CXCL10 also has defensin-like antimicrobial activities
[25] and can enhance Mø killing of intracellular
Leishmania [26].
The purpose of this study was to determine the
effect of smoking on endosomal and cytoplasmic
receptors for nucleic acids. Our results demonstrate
the susceptibility in human AMø of TLR3, but not of
other receptors tested, to smoke-induced down-
regulation.Methods
Research subjects
Studies and consent procedures were performed in
accordance with the Declaration of Helsinki at the VA
Ann Arbor Healthcare System (all bronchoscopies and
some clinically-indicated lung resections) and the
University of Michigan Health System (some clinically-
indicated lung resections, including all lung transplants
and lung volume reduction surgeries) and were ap-
proved by their Institutional Review Boards (FWA
00000348 & FWA 00004969, respectively). All subjects
understood the purpose of the study and gave written
consent before any research procedures. All subjects
underwent a complete history and physical examination
by a Pulmonologist, spirometry, chest imaging, prospect-
ive collection of medication history, and complete blood
count with differential, coagulation studies and chemis-
try panel.
Bronchoalveolar lavage (BAL) cohort
We recruited 13 healthy never-smoker volunteers and
23 subjects with a smoking history who either were
scheduled to undergo bronchoscopy in the evaluation of
solitary pulmonary nodules (n = 16) or who volunteered
(n = 7). Among the 23 subjects who had ever smoked, 18
were active smokers (<six months since quitting) and 5
were former smokers (>six months since quitting). Of
those with any smoking history, subjects (n =10) with
≥10 pack years, a ratio of forced expiratory volume in 1
second to forced vital capacity (FEV1/FVC) >0.7, normal
spirometry, and no clinical diagnosis of COPD represent
control smokers. Subjects (n =13) with a smoking his-
tory, FEV1/FVC <0.7 and abnormal spirometry were
considered to have COPD. All subjects were without
evidence of lung infection, interstitial lung disease or
collagen vascular disease.
Importantly, not all types of experiments were
performed on cells from every subject in this cohort,
and conversely, some subjects were used for more than
one type of experiment. The characteristics of the BAL
subjects used in each type of experiments are sum-
marized in Tables in the Results sections; demographic
and clinical data for this entire cohort are shown in
Additional file 1: Table S1.
Lung tissue cohort
Lung tissue was collected from consented subjects
undergoing clinically-indicated resections for pulmonary
nodules, lung volume reduction surgery, or lung trans-
plantation (n = 25). Using the same definitions as in the
BAL cohort, this cohort comprised seven control smo-
kers and 18 subjects with COPD. This cohort was used
exclusively for flow cytometric analysis of total lung Mø.
Characteristics of this cohort are summarized in the
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dividual subjects are shown in Additional file 2: Table S2.
BAL procedure and cell preparation
BAL was performed in the right middle lobe and lingula
of the volunteers and in whichever of these sites was
contralateral to the nodule in the clinically-indicated
bronchoscopies, in which the research BAL was per-
formed as early as feasible, and always before any bio-
psies or brushings. We instilled 100 ml normal saline
per site, using a 30 ml syringe and gentle manual
suction. BAL fluid was filtered through sterile gauze to
remove mucous, and cells were washed thrice with PBS,
with centrifugation between washes.
BAL cells (>95% AMø by Wright-Giemsa-stained
cytospins) were either immediately processed for flow
cytometry and immunohistochemistry or were cultured
briefly to purify AMø by adherence. For this purpose,
cells were resuspended in complete medium (RPMI
1640 containing 25 mM HEPES, 2 mM l-glutamine, 1
mM pyruvate, 100 U/ml penicillin/streptomycin, 10%
heat-inactivated AB human serum (all from Invitrogen,
Carlsbad, CA), and 55 μM 2-ME (Sigma Chemical, St.
Louis, MO), and were plated at 2 × 105 cells/well in ster-
ile 24-well plates. Cells were incubated for 1.5 h in 5%
CO2 at 37°C, washed to remove nonadherent cells, then
incubated in AIM-V serum-free medium (Invitrogen)
under experimental conditions. For TLR3 stimulation,
adherence-purified AMø were cultured in AIM-V alone
or with poly(I:C) at 50 μg/ml for 24 h.
Lung sample preparation
Lung tissue was dissected free of any areas containing
nodules, cancers or evidence of infection by a Pathologist
before being released to the study. Lung sections weighing
approximately 3 g were dispersed using a Waring blender
in a biosafety cabinet without enzyme treatments, which
we have previously shown produces single cell suspen-
sions of high viability and functional capacity [27,28]. Cells
were filtered through a 40 μm strainer to remove debris
and were resuspended in staining buffer (2% FBS in PBS)
for flow cytometery.
Differentiation and treatment of THP-1 cells
THP-1 cells obtained from ATCC (Manassas, VA) were
grown according to the supplier’s guidelines. Cells were
plated at 4 × 105 cells/well in 24-well plates, and after
adherence, were differentiated by exposure to 150 ng/ml
phorbol myristate acetate (PMA) and 0.01 μM vitamin
D3 for 48 hrs, and then were washed with fresh
complete medium before exposure to various concentra-
tions of cigarette smoke-extract (CSE) for 4 hr. Fresh
CSE was prepared by bubbling the mainstream smoke of
two University of Kentucky Tobacco Health ResearchInstitute standardized cigarettes (lot 2R4F), using a Jaeger-
Baumgartner Cigarette Smoking Machine (C.H. Tech-
nologies, New Jersey) driven by dry compressed air, into
20 ml RPMI 1640; the result was defined as 10% CSE. CSE
was filter-sterilized using a 0.22 μm membrane and was
used the same day.
Quantitative real-time PCR
RNA was isolated using RiboPure kits (Applied Biosystems,
Foster City, CA), TURBO DNA-free (Applied Biosystems)
to remove genomic DNA, and Retroscript kits (Applied
Biosystems) for reverse-transcription. We performed quan-
titative real-time PCR using the Stratagene Mx3000P
(LaJolla, CA), with human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as the endogenous reference,
and commercial primer-probe sets (Taqman chemistry,
Applied Biosystems). Transcript levels were reported rela-
tive to a calibrator of unstimulated THP cells, or AMø
from never smokers, as appropriate, as calculated on the
thermocycler.
Flow cytometry
BAL cells were resuspended in 100 μL staining buffer
{1% FA Buffer (BD Bioscience, San Jose, CA), 1% FCS,
0.01% sodium azide} per tube. We used antibodies
against the following antigens (clones in parentheses):
CD45 (2D1) (eBioscience, San Diego, CA), TLR3
(40C1285.6), TLR7 (polyclonal), TLR9 (26C593.2) (Imgenex
Corp., San Diego, CA), and TLR8 (303F1.14) (Dendritics,
Lyon, France). To detect intracellular receptor expression,
cells were treated with Fixation and Permeabilization
Buffers (eBioscience). In all experiments, we used isotype-
matched controls, analyzed cells on an LSR II flow
cytometer (BD Bioscience), and collected a minimum of
10,000 CD45+ events per sample, using FACS Diva soft-
ware with automatic compensation, and FlowJo analysis
software (Tree Star, Inc., Ashland, OR). Details of instru-
ment setup have been described recently [29].
Immunohistochemistry
Cytospins were immersed in cold acetone followed by
methanol plus hydrogen peroxide. The slides were
stained with biotinylated anti-human TLR3 (Imgenex) or
isotype control antibodies, followed by Universal ABC
peroxidase complex and 3-amino-9-ethylcarbazole per-
oxidase substrate. Slides were counter-stained with
hematoxylin and photographed using an Olympus BX51
digital camera.
CXCL10 analysis
CXCL10 levels were determined using Biosource Multi-
plex Assays (Invitrogen) and a Luminex 200™ (Luminex
Corporation, Austin, TX).
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Statistical analysis was performed using GraphPad Prism
(GraphPad, La Jolla, CA) except as specified. We used
the nonparametric unpaired Mann–Whitney test to de-
termine differences between two groups (smokers versus
never-smokers; healthy subjects versus COPD subjects)
in mRNA and flow cytometry data; the nonparametric
Kruskal-Wallis one-way ANOVA to compare multiple
conditions on THP cells in vitro; and ANOVA with
Bonferroni’s Multiple Comparison post-hoc testing to
determine differences between smokers and never-
smokers in stimulated cytokine secretion. We used
Spearman non-parametric analysis to correlate TLR3
mRNA and protein expression with clinical variables
and performed linear regression using SPSS (IBM Corp.;
Armonk, NY). A two-tailed p value of < 0.05 was consi-
dered significant.
Results
TLR3 expression is selectively decreased in AMø of
smokers
To test whether cigarette smoking impacts expression
by human AMø of TLRs implicated in defense against
respiratory viruses, we first analyzed adherence-purified
AMø obtained by BAL of 11 current or former smoking
subjects and six never-smokers (Table 1) using quan-
titative real-time PCR. Results showed significantly
decreased TLR3 mRNA transcripts in smokers com-
pared with never-smokers (p = 0.0015; Mann–Whitney
test) (Figure 1A), but no significant differences in tran-
scripts for TLR7, TLR8 or TLR9, which are also found
in the endosome (Figure 1A). We also found no signifi-
cant differences between smokers and never-smokers in
mRNA transcripts for the cytoplasmic dsRNA receptors
RIG-I, MDA-5 and PKR (Additional file 3: Figure S1).
These findings were supported by two measures of AMø
protein expression. Flow cytometry (Additional file 4:Table 1 Characteristics of BAL subjects used for RNA
studies
Group Smokers Never-smokers p value
Subjects, n 11 6
Sex ratio, M/F 11/0 2/4 0.003
Age, years (SD) 65.5 (7.2) 37.7 (12) 0.002
Smoking, pack-years (SD) 65.5 (23.1) 0 (0) 0.0008
Smoking status (Former/Current) 2/9 0/0 0.003
FEV1, % pred. (SD) 57 (22.1) 101 (8.7) 0.002
FEV1/FVC% (SD) 58.5 (15.6) 86.8 (4.9) 0.0007
ICS use (yes/no) 7/4 0/6 0.02
ICS Inhaled Corticosteroid Use, M Male, F Female. Data are represented as
mean (SD), ratio of current smokers to former smokers, or fraction of ICS users
(yes/no). All FEV1 values are pre-bronchodilator. p values calculated using
Mann Whitney test.Figure S2) permitted identification of specific staining
for TLR3 and TLR9 amongst AMø of never-smokers,
although expression of TLR7 was very low (Additional
file 4: Figure S2, middle panel) in both groups, and was
not analyzed further. Comparing BAL samples from
smokers (n = 13), and never-smokers (n = 10) (Table 2),
we found a significantly decreased percentage (p < 0.0001,
Mann–Whitney test) of AMø positive for intracellular
TLR3 in AMø of smokers (Figure 1B). Note that these
experiments contain some of the same subjects studied in
Table 1, as well as other BAL subjects, as described in
Methods; for additional details about individual subjects,
see Additional file 1: Table S1). TLR3 was not detected on
the surface of unpermeabilized AMø of either group (not
shown). There were no differences between smokers (n = 6)
and never-smokers (n = 5) in the percentage of AMø
expressing intracellular TLR9 (Figure 1B) (or TLR7 and
TLR8, data not shown). Similarly, immunohistochemical
staining of BAL cytospins (Additional file 1: Table S1) de-
monstrated greatly reduced TLR3 expression in the AMø
from smokers, relative to AMø from the never-smokers
(Figure 1C). These independent data indicate that reduction
in TLR3 protein expression measured by flow cytometry
did not result simply from greater autofluorescence in
AMø of smokers.
In univariate analyses including both smokers and
never-smokers, TLR3 RNA transcripts correlated inversely
with both FEV1 % predicted and subject age (Figure 2A-B).
Considering only those with a history of smoking, there
was no correlation with pack-years (Figure 2C). However,
in a linear regression, none of the variables (smoker versus
never-smoker, age, sex, FEV1 % predicted) reached statis-
tical significance for mRNA transcripts. AMø positivity for
TLR3 protein did not correlate in univariate analyses with
FEV1 % predicted (Figure 2D) or pack-years of smoking
exposure (Figure 2F), but did correlate with subject age
(Figure 2E). In a linear regression, smoking status (smoker
vs. never-smoker) was strongly associated with TLR3+
AMø (p < 0.0001) and subject age was also significant (p =
0.035), but sex and FEV1 % predicted remained insignifi-
cant. When we analyzed smokers with COPD versus
smokers without COPD, no significant differences were
seen in TLR3 mRNA transcripts (COPD, 0.23 ± 0.16 vs. no
COPD, 0.49 ± 0.49, mean ± SEM dRn; p = 0.52, unpaired
t test) or flow cytometric results (COPD, 12.2 ± 12.2 vs.
non-COPD, 10.4 ± 5.2; mean ± SEM % TLR3-positive
AMø, p = 0.87, unpaired t test). Despite the use of inhaled
corticosteroids (ICS) by ~50% of the smoking sub-
jects, the decrease in the fraction of TLR3+ AMø of
smokers was not a result of steroid usage (p = 0.79,
determined by t-test comparing TLR3 mRNA tran-
script expression between ICS users and non-users;
p = 0.92 when comparing TLR3 protein measurements
by flow cytometry).
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Figure 1 AMø of current smokers show reduced expression of TLR3 mRNA transcripts and intracellular protein relative to AMø of
never-smokers. A. mRNA transcripts. RNA was isolated from AMø, depleted of contaminating genomic DNA, reverse-transcribed and analyzed
by quantitative real-time RT-PCR using Taqman chemistry and specific primer-probe sets, normalized to GAPDH transcripts. Data are expressed on
the horizontal axis as mean ± SEM for relative quantity (dRn), calculated in comparison to a single never-smoker who was arbitrarily designated
the reference sample. Never-smokers (n = 6), red bars; smokers (n = 11), blue bars. *, p < 0.05 by Mann–Whitney test. B. Intracellular TLR3 (top
panel) and TLR9 (bottom panel) expression by flow cytometry. AMø were permeabilized, stained for TLR3 and TLR9 expression and analyzed by
flow cytometry. Data are expressed as TLR-positive AMø as mean ± SEM, never-smokers (n = 10 for TLR3, n = 5 for TLR9), red circles; smokers
(n = 13 for TLR3, n = 6 for TLR9), blue circles. *, p < 0.05 by Mann–Whitney test. C. Immunohistochemical staining. Cytospins from a representative
smoker (right) and a never-smoker (left), stained for intracellular TLR3 expression using AEC (red product) and hematoxylin (original 20 X). Top
row, isotype control staining, bottom row, specific TLR3 staining. Representative of three experiments with similar results.
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effect of smoking on AMø expression of TLR3. However,
due to the distribution of our subjects, we were unable
to exclude the possibility that our findings resulted from
the preponderance of women in the never-smoker group
and of men among the smokers in this cohort, or from
the significant difference in ages between the volunteer
and clinical subjects.Reduced TLR3 expression in lung Mø correlates with
smoking status but not COPD stage
In apparent contradiction to our findings, a recent paper
primarily using immunohistochemistry in lung tissue sec-
tions reported that the percentage of TLR3-positive lung
Mø were significantly increased in smokers compared
with never-smokers [30]. To address this discrepency and
the questions about the possible effects of age and sex in
Table 2 Characteristics of BAL subjects used for flow
cytometry studies
Group Smokers Never-smokers p value
Subjects, n 13 10
Sex ratio, M/F 11/2 1/9 0.0006
Age, years (SD) 60.3 (8.9) 42.2 (13.7) 0.002
Smoking, pack-years (SD) 47.4 (33.7) 0 (0) 0.0001
Smoking status (Former/Current) 3/10 0/0 0.0001
FEV1, % pred. (SD) 83.5 (23.6) 100.7 (10.5) 0.077
FEV1/FVC% (SD) 72.5 (14.3) 84.2 (5.7) 0.0249
ICS use (yes/no) 4/9 0/10 N.S.
ICS Inhaled Corticosteroid Use; M Male, F Female. Data are represented as
mean (SD), ratio of current smokers to former smokers, or fraction of ICS users
(yes/no). All FEV1 values are pre-bronchodilator. p values calculated using
Mann Whitney test.
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(n = 25) undergoing clinically-indicated lung resection
procedures (Table 3). This cohort also had the advantage
of having more nearly balanced ratios of male and female
subjects, as well as a wide range of spirometry values. We
used mechanical disaggregation of tumor-free lung paren-
chyma to produce a single cell suspension of high viability
containing both AMø and interstitial lung Mø, which we
identified as autofluorescent, CD45+, high side scatter
cells.
Flow cytometric analysis permitted objective quantifi-
cation of the percentage of individual lung Møs positive
for intracellular TLR3, relative to simultaneously analyzed
isotype-control monoclonal antibodies (Figure 3A, B). We
found the percentage of TLR3-positive lung Møs from
current smokers was significantly reduced (p = 0.006)
compared to the percentage of TLR3-positive lung Møs
from former smokers (Figure 3C). By contrast, considering
these same individuals, there were no significant dif-
ferences in percentages of lung Mø expressing TLR3
between those with normal pulmonary function and those
with COPD (Figure 3D). Nor was there a correlation
between the percentage of TLR3-positive lung Mø by flow
cytometry and either FEV1 % predicted or duration of
smoking in pack-years (Additional file 5: Figures S3A &
B). In a linear regression, smoking status (current vs.
former) was significantly associated with TLR3 positivity
(p = 0.016) and was not affected by age, FEV1 % predicted,
sex, or pack-years. These independent data agree with and
extend results of our BAL experiments and collectively
show that active smoking reduces TLR3 expression by
resident human lung Mø.
Exposure to CSE specifically reduces expression of TLR3
mRNA transcripts by differentiated human THP-1 cells
To explore the effect of acute smoke-exposure in vitro,
we used the well-characterized system of differentiatingthe human Mø cell line THP-1 by treatment with PMA
plus vitamin D3. In four independent experiments, we
found that CSE at concentrations of 1.25% and 2.5% sig-
nificantly decreased expression of TLR3 transcripts
(Figure 4A), but had no effect on transcripts of TLR7,
TLR8 or TLR9 (Figures 4B-D). CSE at these concentra-
tions had no effect on viability as assessed by trypan blue
exclusion (not shown). CSE also had no significant effect
on mRNA transcripts for RIG-I, MDA-5 or PKR at con-
centrations up to 2.5% CSE (Figure 4E-G). Thus, the
effect of smoke exposure on TLR3 mRNA levels can be
induced within as little as four hours in THP-1 cells
differentiated to a mature Mø phenotype. These findings
indicate that smoking reduces Mø TLR3 expression
directly, and not secondarily due to an effect on another
lung cell type or on the lung microbiome.
AMø of smokers show reduced CXCL10 production in
response to poly(I:C) stimulation in vitro
Finally, we investigated whether decreased TLR3 expres-
sion on the AMø of smokers would affect CXCL10
production following poly(I:C) stimulation. These exper-
iments were performed using AMø from subjects in the
BAL cohort (Additional file 2: Table S2). CXCL10 con-
centrations were close to the level of detection in
unstimulated cells from both smokers (n = 5) and never-
smokers (n = 4) (Table 4) and did not differ significantly
(Figure 5). Following poly(I:C) stimulation, AMø from
never-smokers showed a 1000-fold increase in CXCL10
production, and differed significantly from the response
of AMø from smokers, which showed only a 10-fold in-
crease from unstimulated levels (Figure 5). These results
illustrate a functional consequence of the difference in
TLR3 expression between the two groups.
Discussion
We demonstrate that smoking reduces expression by
human lung Mø of TLR3, a receptor for microbial
dsRNA and endogenous danger signals. Relative to AMø
of never-smokers, AMø of current smokers showed re-
duced TLR3 mRNA and protein, and lower secretion of
CXCL10 in response to the viral dsRNA analogue poly(I:
C). Smoking did not significantly reduce AMø expres-
sion of other receptors for viral nucleic acids in the cyto-
plasm (RIG-I, MDA-5 or PKR) or endosome (TLR7,
TLR8 or TLR9). In a separate cohort, TLR3 protein
expression by total lung Mø was also reduced in active
smokers, relative to former smokers. TLR3 protein
expressed as the percentage of postive lung Mø did not
correlate significantly in either cohort with a diagnosis
of COPD, FEV1% predicted or total history of smoking
expressed as pack-years. The direct nature of the smok-
ing effect was shown in vitro using differentiated cells of
the human Mø line THP-1. These findings identify a
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Figure 2 AMø TLR3 expression does not correlate with lung function or total duration of smoking exposure. AMø were harvested,
processed and analyzed as described in the legend to Figure 1. A-C. TLR3 mRNA transcripts by quantitative real-time PCR (smokers, n = 11;
never-smokers, n = 6, except in panel C, which includes only current or former smokers). D-F. Flow cytometric analysis of TLR3 protein expression
(smokers, n = 13; never-smokers, n = 10, except in panel F which includes only current or former smokers). A, D: FEV1 % predicted; B, E:
participant age (years); C, F: smoking history (pack-years); note the difference in the vertical scale of panel F. Blue circles, smokers; red crosses,
never-smokers. p values by Spearman correlation.
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lung host defenses.
Our findings address the intersection of two highly
prevalent clinical issues, host defense against respiratory
viruses and smoking. Respiratory viruses are implicated,
alone or as mixed infections, in most COPD exacerba-
tions, including those of greatest severity [31,32]. Viral
respiratory infections are also the leading cause of
asthma exacerbations in adults and children [33,34],
including those requiring hospitalization [35]. Althoughonly some smokers develop COPD, those who continue
to smoke sustain more frequent respiratory infections
and faster lung function decline [36]. Smoking is also a
key contributor to morbidity in asthma [37]. Asthmatic
smokers experience worse symptom control, greater risk
of hospitalization, and increased resistance to the thera-
peutic effects of inhaled corticosteroids [38-41]. Finally,
even in individuals with normal spirometry, smoking is
an independent risk factor for increased number and
severity of respiratory infections [3]. Hence, these results
Table 3 Characteristics of surgical lung tissue subjects
Group Smokers with COPD Smokers without COPD p value
Subjects, n 18 7
Sex ratio, M/F 10/8 5/2 0.49
Age, years (SD) 61.8 (9.4) 54.4 (9.1) 0.74
Smoking, pack-years (SD) 60.3 (41.4) 44.5 (23.9) 0.47
Smoking status (Former/Current) 4/14 3/4 0.11
FEV1, % pred. (SD) 41.8 (27.7) 95.4 (11.2) 0.0008
FEV1/FVC% (SD) 42.5 (18.6) 76.0 (5.2) 0.0002
ICS use (yes/no) 12/6 1/6 0.02
ICS Inhaled Corticosteroid Use, M Male, F Female. Data are represented as mean (SD), ratio of current smokers to former smokers, or fraction of ICS users (yes/no).
All FEV1 values are pre-bronchodilator. p values calculated using Mann Whitney test.
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smoking absolutely, regardless of pulmonary function or
specific diagnosis.
Optimal defense against respiratory viruses requires
coordination of multiple elements of innate and adaptive
immunity [42], especially prompt production by epithelial0 102 103 104 105
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A specific anti-viral role of AMø has been confirmed ex-
perimentally by cellular depletion in two animal models
[50,51], but in a murine model of respiratory syncytial
virus pneumonia, AMø depletion reduced early antiviral
responses, increased viral load, but had no effect on late
outcomes [52]. Hence, the significance of the current find-
ings may vary with the particular viral pathogen. Add-
itional studies will be needed to determine whether the
effect we found on TLR3 expression translates into defect-
ive responses by the AMø of smokers to intact respiratory
viruses.These results expand the known effects of cigarette
smoking on AMø function, which are clearly complex.
Two studies using Affymetrix Human Genome U133
Plus 2.0 GeneChips found AMø from human smokers to
have distinctive, globally altered gene expression profiles
relative to non-smokers [53,54]. Interestingly, TLR3 is
not mentioned as a differentially expressed gene in ei-
ther study. Disparity from our results likely relates to the
difference in methodology; importantly, we showed very
reduced TLR3 protein expression. The more pro-
nounced reduction we found in TLR3 protein relative to
mRNA implies the possibility of post-transcriptional
Table 4 Characteristics of BAL subjects used for in vitro
stimulation studies
Group Smokers Never-smokers p value
Subjects, n 5 4
Sex ratio, M/F 5/0 2/2 0.13
Age, years (SD) 60 (11) 39.5 (12.1) 0.06
Smoking, pack-years (SD) 47.4 (35.2) 0 (0) 0.02
Smoking status (Former/Current) 0/5 0/0 0.007
FEV1, % pred. (SD) 66.6 (30.6) 106.5 (12) 0.06
FEV1/FVC% (SD) 61.8 (19) 81.0 (7.5) 0.10
ICS use (yes/no) 3/2 0/4 0.10
ICS Inhaled Corticosteroid Use, M Male, F Female. Data are represented as
mean (SD), ratio of current smokers to former smokers, or fraction of ICS users
(yes/no). All FEV1 values are pre-bronchodilator. p values calculated using
Mann Whitney test.
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http://respiratory-research.com/content/14/1/33smoking-induced downregulation, an important issue for
future studies.
AMø of human smokers are often described as being
“activated” [55-57], but both they and AMø from COPD
patients show impaired bacterial uptake and killing
[58,59]. Production of TNF-α and IL-6 by AMø of
smokers (and COPD patients, which often mixed current
and former smokers) equaled or exceeded that of non-
smokers, but was strikingly less inhibitable by steroids
[60,61]. Increased secretion of IL-8 and other neutrophil-C
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Figure 5 Production of CXCL10 by AMø of smokers in response
to poly(I:C) stimulation is impaired. AMø from never-smokers
(n = 4) (white and red columns) and smokers (n = 5) (light and dark
blue columns) were cultured for 24 h in either complete medium
alone or with poly(I:C). Supernatants were collected and CXCL10
protein was measured by Luminex assay; results are expressed as
the fold-increase in CXCL10 over the unstimulated control condition;
note the logarithmic scale of the vertical axis. Data are mean ± SEM.
One-way ANOVA with Bonferroni’s Multiple Comparison post-hoc
testing was used to compare differences among groups, *, p < 0.01.attracting chemokines by AMø of human smokers has
been shown in most [62,63] but not all [64] studies. Thus,
smoking appears to make AMø less likely to respond effi-
ciently to pathogens but more likely to enhance sustained
inflammation.
TLR3 has been shown experimentally to be essential
for optimal protection against some but not all viruses,
even those with a dsRNA genome [17]. Moreover, under
some circumstances TLR3 may be responsible for exa-
ggerated inflammation [65], and anti-TLR3 blocking
antibody is being developed for therapeutic use [66].
Importantly, TLR3 is a receptor not only for microbial
dsRNA, but also for dsRNA from necrotic host cells
[67], an example of an endogenous danger-associated
molecular pattern. This finding assumes increased signifi-
cance based on the recognition of increased apoptotic cell
death in emphysema [68] and decreased clearance of
apoptotic cells by AMø of smokers [69-71], a defect
postulated to foster lung injury and emphysema progres-
sion [71,72]. Hence, the putative detrimental effect of
reduced TLR3 expression by AMø of smokers on antiviral
defenses might be partially offset by reduced responsive-
ness to necrosis-induced lung inflammation, an intriguing
possibility that will require considerably greater investiga-
tion. Our finding that the percentage of TLR3-positive
AMø was increased in former smokers when compared to
active smokers agrees with the partial resolution of other
smoking-induced AMø defects on smoking cessation [73].
These data are also congruent with the observation that
smoking but not COPD decreases AMø expression of
TLR2, but not of TLR4 [74]. The molecular mechanisms
for down regulation by active smoking of TLR3 (this
study) and TLR2 [74] remain unclear.
Our data partially differ from those of Koarai and
colleagues, who recently reported increased TLR3 ex-
pression by AMø of smokers that correlated positively
with smoking history and inversely with DLCO but not
FEV1 % predicted [30]. Our results agree in finding no
differences in AMø TLR3 expression among smokers
based on the presence or absence of spirometrically-
defined COPD. That study examined paraffin-fixed
sections using a polyclonal anti-TLR3 antibody and
immunohistochemistry, whereas we analyzed freshly
isolated cells using the same monoclonal antibody in
both of our cohorts. Hence, the disparity regarding
TLR3 expression results might relate to antigen avail-
ability. Our studies differ in the cell type used for
in vitro exposure to CSE (in that study MDMø), incuba-
tion time (24 hr vs. 4 hr in the current study) and CSE
concentration (5% vs. a significant effect at 1.25% in the
current study). These disparities make comparison diffi-
cult, as do multiple differences in design and endpoints
of the experiments testing poly(I:C)-stimulated mediator
production. One other study found that CSE reduced
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that MDMø of smokers had reduced mRNA expression
of RIG-I and MDA-5, relative to MDMø of never-
smokers [75]. That study does not mention TLR3
expression, which presumably was not altered in either
case. Differences from our results likely reflect disparity
both in cell type studied and possibly in methodology, as
those results were obtained by Affimetrix assay.
The current findings are interesting in regard to two
recent murine studies. Gaschler and colleagues found
attenuated in vitro secretion of TNF-α, IL-6 and CCL5
in response to poly(I:C) by AMø from smoke-exposed
mice, but did not find decreased TLR3 expression [76].
That disparity from our results may reflect a species
difference. Kang and colleagues found that cigarette
smoke selectively augmented airway and alveolar inflam-
mation induced by viral MAMPs and influenza virus, as
measured by induction of type I IFN, IFN-γ, IL-18 and
IL-12/IL-23 p40 and PKR activation [77]. Further ana-
lysis using knockout mice indicated a role for both acute
TLR3-dependent and chronic TLR3-independent path-
ways, as well as a pathway dependent on mitochondrial
antiviral signaling protein (MAVS), IL-18Rα, IFN-γ and
PKR [77]. That important study, however, did not measure
TLR3 expression by AMø, and its findings likely reflect
the interaction of multiple cell types in vivo.
Considerable evidence indicates the importance of
CXCL10 in antiviral host defense but also in develop-
ment or prevention of certain lung diseases [78,79].
CXCL10 is one of three chemokines, along with CXCL9
and CXCL11, that are highly induced by IFN-γ, as well
as by types I and III IFNs [49,80]. Of note, however,
CXCL10 production is also induced directly by infection
of human AMø by rhinovirus, of murine AMø by RSV
and of human MDMø by influenza or HIV [19,20,81-83],
making this cytokine a suitable endpoint to test the func-
tional importance of the observed TLR3 downregulation.
A key action of CXCL10 is inflammatory cell recruitment,
acting via CXCR3, which is found on Mø, CD8+ T cells,
activated CD4+ T cells (especially TH1 cells), NK cells and
plasmacytoid dendritic cells [84]. CXCR3 is essential for
recruitment of antigen-specific CD4+ T cells to the lungs
in a murine model of parainfluenza pneumonia [85]. In a
model of Coxsackievirus infection, CXCL10 was shown to
limit viral replication via NK cell recruitment [24].
Markedly reduced induction of CXCL10 in AMø from
smokers is of interest in the context of other recent
human studies. CXCL10 is one of several M1-associated
genes down-regulated in AMø of healthy smokers and
even more so, in smokers with COPD, relative to healthy
never-smokers [54]. Although significantly increased
CXCL10 concentrations have been found in the sputum
of COPD patients, when compared with nonsmokers
but not with smokers without obstruction [86], theorigin of that chemokine is unclear, as it is also pro-
duced by epithelial cells that significantly outnumber
Mø in the airways. Both by showing the role of reduced
TLR3 expression and by studying AMø, we extend a
study of gene expression by MDMø, which found
reduced expression of CXCL10 at baseline in smokers
relative to never-smokers, and also that CSE reduced
IFN-γ-induced CXCL10 production by MDMø of never-
smokers [75].
Our study has several limitations. One is the absence
of never-smokers from our surgical cohort, who were
recruited before clinically-indicated resections. Another
is the predominance in our BAL cohort of female never-
smokers (11 of 13 subjects) versus a predominance of
male current smokers with preserved lung function
(eight of nine subjects) and COPD patients (11 of 11
subjects). Concerns that differences in sex or age could
confound our BAL results should be reduced by the
congruent effect of smoking in our surgical cohort,
which comprised 40% female subjects and which showed
no significant effect of age on TLR3 expression by lung
Mø. Moreover, at equivalent levels of tobacco exposure,
women appear to be at greater risk of lung function im-
pairment {reviewed in [87]}, the opposite of what would
be expected if the current finding were a male-specific
effect. Although we cannot formally exclude the possibi-
lity that differences in subject age explain the reduced
expression of CXCL10 in response to TLR3, we consider
that possibility unlikely, as serum levels of CXCL10
increase with age [88,89]. Other limitations are the
absence of DLCO measurements, which precludes
comparison of our results with those of Koarai and
colleagues [30] on this point, and that because post-
bronchodilator FEV1 values were not available on all
subjects, we have presented and analyzed exclusively
pre-bronchodilator FEV1 values.Conclusions
Active smoking reduces expression of TLR3 by human
lung Mø, assayed both as AMø harvested by BAL and as a
mixture of AMø and interstitial lung Mø from surgical
tissue. This effect occurs via both down-regulation of
mRNA transcripts, which can be induced in vitro within
four hours, and from a more pronounced effect on
TLR3 protein expression, which appears to be at least
partially reversible on smoking cessation. Reduction in
lung Mø TLR3 expression may be one mechanism con-
tributing to the increased incidence of viral respiratory
infections in smokers and to viral induction of acute
exacerbations of COPD. Defining the effect of smoking
on the phenotype of human AMø and other lung cell
types is a crucial step in the translation of basic science
into therapies.
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181: A3875.
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beck@denver.edu.Additional files
Additional file 1: Table S1. Summary of all BAL subjects demographics,
smoking histories, spirometry & current smoking status. ICS, inhaled
corticosteroid use; FC, flow cytometry; IHC, immunohistochemistry.
Summarized data are shown in bold and are represented as mean (SD),
ratio of current smokers to former smokers, or fraction of ICS users
(yes/no). All FEV1 values are pre-bronchodilator.
Additional file 2: Table S2. Summary of all lung tissue subject
demographics, smoking histories, spirometry & current smoking status.
ICS, inhaled corticosteroid use. M, Male; F, Female. Summarized data are
shown in bold and are represented as mean (SD), ratio of current
smokers to former smokers, or fraction of ICS users (yes/no). All FEV1
values are pre-bronchodilator.
Additional file 3: Figure S1. AMø of current smokers show no
reduction in mRNA expression of cytoplasmic dsRNA receptors, relative
to AMø of never-smokers. RNA from AMø was isolated, depleted of
contaminating genomic DNA, reverse-transcribed and analyzed by
quantitative real-time RT-PCR using Taqman chemistry and specific
primer-probe sets, normalized to GAPDH transcripts. Data are expressed
on the horizontal axis as mean ± SEM for relative quantity (dRn),
calculated in comparison to a single never-smoker who was arbitrarily
designated the reference sample. Never-smokers (n = 6), red bars;
smokers (n = 11), blue bars. The Mann–Whitney test was used to calculate
statistical significance.
Additional file 4: Figure S2. Representative flow cytometry results.
AMø were permeabilized, stained for expression of TLR3 (left-hand
panels), TLR 7 (middle panel) and or TLR9 (right-hand panels), and
analyzed by flow cytometry, gating on AMø (CD45+, high side scatter
cells). A,B; specific staining (red line), isotype control staining (blue line).
A, never-smoker, B, smoker.
Additional file 5: Figure S3. Lack of correlation of spirometry or total
smoking history with lung AMø TLR3 expresssion in surgical cohort. Total
lung Mø were harvested from excess lung tissue removed surgically for
clinical indications as decribed in the legend to Figure 3. Lung Mø were
permeabilized, stained for TLR3 expression and analyzed by flow
cytometry, gating on CD45+, high side-scatter cells. Data are shown as
the percentage of TLR3-positive lung Mø on the vertical axis versus A,FEV1 % predicted; B, smoking history in pack-years. In panel A, circles
represent current smokers and “x” respresents former smokers. In panel B,
all subjects are shown as inverted triangles, regardless of smoking status
(active vs. former); in both panels, n = 25.Abbreviations
AMø: Alveolar macrophage(s); BAL: Bronchoalveolar lavage; COPD: Chronic
obstructive pulmonary disease; CSE: Cigarette smoke extract; Ds: Double-
stranded; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital
capacity; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase;
Mø: Macrophage(s); MDA-5: Melanoma differentiation-associated gene 5;
MDMø: Monocyte-derived macrophage(s); NK: Natural killer; PKR: Double-
stranded RNA-dependent protein kinase; PMA: Phorbol myristate acetate;
poly(I:C): Polyinosinic acid:cytidylic acid; RIG-I: Retinoic acid-inducible gene I;
TLR3: Toll-like receptor 3.
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